TY - JOUR
T1 - CoDE-seq, an augmented whole-exome sequencing, enables the accurate detection of CNVs and mutations in Mendelian obesity and intellectual disability
AU - Montagne, Louise
AU - Derhourhi, Mehdi
AU - Piton, Amélie
AU - Toussaint, Bénédicte
AU - Durand, Emmanuelle
AU - Vaillant, Emmanuel
AU - Thuillier, Dorothée
AU - Gaget, Stefan
AU - De Graeve, Franck
AU - Rabearivelo, Iandry
AU - Lansiaux, Amélie
AU - Lenne, Bruno
AU - Sukno, Sylvie
AU - Desailloud, Rachel
AU - Cnop, Miriam
AU - Nicolescu, Ramona
AU - Cohen, Lior
AU - Zagury, Jean François
AU - Amouyal, Mélanie
AU - Weill, Jacques
AU - Muller, Jean
AU - Sand, Olivier
AU - Delobel, Bruno
AU - Froguel, Philippe
AU - Bonnefond, Amélie
N1 - Funding Information:
The authors would like to thank the children, young adults, and their families who participated in this study. We thank Frédéric Allegaert and Nicolas Larcher for their contribution to DNA extraction. We are also grateful to Françoise Boidein, Marie-Bertille Dehouck and Christine Vassel for collecting clinical data. This work was supported by grants from the French National Research Agency ( ANR-10-LABX-46 [European Genomics Institute for Diabetes] and ANR-10-EQPX-07-01 [LIGAN-PM] , to PF), from the European Research Council ( ERC GEPIDIAB – 294785 , to PF; ERC Reg-Seq – 715575 , to AB) and from FEDER (to PF). AB was supported by Inserm .
Funding Information:
The authors would like to thank the children, young adults, and their families who participated in this study. We thank Frédéric Allegaert and Nicolas Larcher for their contribution to DNA extraction. We are also grateful to Françoise Boidein, Marie-Bertille Dehouck and Christine Vassel for collecting clinical data. This work was supported by grants from the French National Research Agency (ANR-10-LABX-46 [European Genomics Institute for Diabetes] and ANR-10-EQPX-07-01 [LIGAN-PM], to PF), from the European Research Council (ERC GEPIDIAB – 294785, to PF; ERC Reg-Seq – 715575, to AB) and from FEDER (to PF). AB was supported by Inserm.
Publisher Copyright:
© 2018 The Authors
PY - 2018/7/1
Y1 - 2018/7/1
N2 - Objective: The molecular diagnosis of extreme forms of obesity, in which accurate detection of both copy number variations (CNVs) and point mutations, is crucial for an optimal care of the patients and genetic counseling for their families. Whole-exome sequencing (WES) has benefited considerably this molecular diagnosis, but its poor ability to detect CNVs remains a major limitation. We aimed to develop a method (CoDE-seq) enabling the accurate detection of both CNVs and point mutations in one step. Methods: CoDE-seq is based on an augmented WES method, using probes distributed uniformly throughout the genome. CoDE-seq was validated in 40 patients for whom chromosomal DNA microarray was available. CNVs and mutations were assessed in 82 children/young adults with suspected Mendelian obesity and/or intellectual disability and in their parents when available (n total = 145). Results: CoDE-seq not only detected all of the 97 CNVs identified by chromosomal DNA microarrays but also found 84 additional CNVs, due to a better resolution. When compared to CoDE-seq and chromosomal DNA microarrays, WES failed to detect 37% and 14% of CNVs, respectively. In the 82 patients, a likely molecular diagnosis was achieved in >30% of the patients. Half of the genetic diagnoses were explained by CNVs while the other half by mutations. Conclusions: CoDE-seq has proven cost-efficient and highly effective as it avoids the sequential genetic screening approaches currently used in clinical practice for the accurate detection of CNVs and point mutations.
AB - Objective: The molecular diagnosis of extreme forms of obesity, in which accurate detection of both copy number variations (CNVs) and point mutations, is crucial for an optimal care of the patients and genetic counseling for their families. Whole-exome sequencing (WES) has benefited considerably this molecular diagnosis, but its poor ability to detect CNVs remains a major limitation. We aimed to develop a method (CoDE-seq) enabling the accurate detection of both CNVs and point mutations in one step. Methods: CoDE-seq is based on an augmented WES method, using probes distributed uniformly throughout the genome. CoDE-seq was validated in 40 patients for whom chromosomal DNA microarray was available. CNVs and mutations were assessed in 82 children/young adults with suspected Mendelian obesity and/or intellectual disability and in their parents when available (n total = 145). Results: CoDE-seq not only detected all of the 97 CNVs identified by chromosomal DNA microarrays but also found 84 additional CNVs, due to a better resolution. When compared to CoDE-seq and chromosomal DNA microarrays, WES failed to detect 37% and 14% of CNVs, respectively. In the 82 patients, a likely molecular diagnosis was achieved in >30% of the patients. Half of the genetic diagnoses were explained by CNVs while the other half by mutations. Conclusions: CoDE-seq has proven cost-efficient and highly effective as it avoids the sequential genetic screening approaches currently used in clinical practice for the accurate detection of CNVs and point mutations.
KW - Augmented whole-exome sequencing
KW - Copy number variation
KW - Intellectual disability
KW - Molecular diagnosis
KW - Next-generation sequencing
KW - Obesity
UR - http://www.scopus.com/inward/record.url?scp=85047066208&partnerID=8YFLogxK
U2 - 10.1016/j.molmet.2018.05.005
DO - 10.1016/j.molmet.2018.05.005
M3 - Article
AN - SCOPUS:85047066208
SN - 2212-8778
VL - 13
SP - 1
EP - 9
JO - Molecular Metabolism
JF - Molecular Metabolism
ER -